Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was the target of some unusual options trading on Tuesday. Stock investors bought 724 call options on the company. This is an increase of approximately 892% compared to the average volume of 73 call options.
Shares of NASDAQ:RARE opened at $41.56 on Wednesday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -5.62 and a beta of 2.16. The business has a 50 day moving average price of $39.77 and a 200 day moving average price of $51.22. The company has a quick ratio of 6.64, a current ratio of 6.79 and a debt-to-equity ratio of 0.04. Ultragenyx Pharmaceutical has a twelve month low of $35.41 and a twelve month high of $74.50.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. The business had revenue of $25.80 million during the quarter, compared to the consensus estimate of $28.88 million. During the same period in the prior year, the firm earned ($1.74) earnings per share. The business’s quarterly revenue was up 119.4% on a year-over-year basis. Analysts anticipate that Ultragenyx Pharmaceutical will post -7.28 EPS for the current year.
In related news, CEO Emil D. Kakkis acquired 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were acquired at an average cost of $43.63 per share, with a total value of $218,150.00. Following the purchase, the chief executive officer now owns 472,479 shares of the company’s stock, valued at $20,614,258.77. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.80% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of RARE. Rothschild & Co. Asset Management US Inc. increased its position in Ultragenyx Pharmaceutical by 89.5% during the second quarter. Rothschild & Co. Asset Management US Inc. now owns 105,275 shares of the biopharmaceutical company’s stock worth $6,685,000 after acquiring an additional 49,735 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 12.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,511 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 515 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Ultragenyx Pharmaceutical by 6.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,325 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 212 shares during the period. Aperio Group LLC raised its position in shares of Ultragenyx Pharmaceutical by 21.4% during the second quarter. Aperio Group LLC now owns 9,130 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 1,608 shares during the last quarter. Finally, Sector Gamma AS raised its position in shares of Ultragenyx Pharmaceutical by 20.8% during the second quarter. Sector Gamma AS now owns 79,653 shares of the biopharmaceutical company’s stock valued at $5,058,000 after buying an additional 13,718 shares during the last quarter.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Featured Story: How to invest using market indexes
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.